“Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration,” CNN reports.New York Times: “The Trump administration’s agreements with the drugmakers Novo Nordisk and Eli Lilly would save consumers and the government considerable money on Wegovy, Zepbound and two obesity pills that are expected to win regulatory approval in the coming months.”